Promoter holding
64.27%
LL
Lyrus Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Lyruslife: trust score, financial health, credit view, compliance, directors, growth and distress signals - ge…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Lyruslife — 360° Intelligence Report
Generated from MCA filings & public records72/100
Trust Score
Moderate
Lyruslife is assessed as Moderate with a Trust Score of 72/100. Lyruslife is an active private limited indian non-government company incorporated in 2015, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.
Report generated on 09 Jul 2026 from the latest processed filings. Lyrus Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
72/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
25/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
25/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 25/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 38%).
- Externally credit-rated (BB).
Charges position: 1 open (30.00 cr) · 2 satisfied (56.63 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Canara Bank | 1 | 48.0 cr |
| Others | 1 | 48.0 cr |
| State Bank Of India | 1 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| DASARI RAMESH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HEMANTH KUMAR BOTHRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| LEELA KANWAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
39 allotment(s) · 2 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Lyrus Life Sciences Limited, Uk | Subsidiary Company | 74.00% |
| Avallon Pharmaceuticals Pty Limited | Associate Company | 74.00% |
Key managerial personnel: HEMANTH KUMAR BOTHRA (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 70 · Distress 60
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Operating for 11+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
1 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence77/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment42/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 30.00 cr already registered.
- Compliance record supports lending.
Investor view55/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
10 Feb 2025
Charge satisfied
State Bank Of India
07 Feb 2025
Charge created
Others - 30.00 cr
28 Feb 2024
Charge created
State Bank Of India - 18.50 cr
26 Feb 2024
Charge satisfied
Canara Bank
05 Jan 2023
Securities allotted
75000 Debentures - 75.00 Lakh raised
23 Dec 2022
Securities allotted
400000 Debentures - 4.00 cr raised
12 Dec 2022
Securities allotted
50000 Debentures - 50.00 Lakh raised
03 Dec 2022
Securities allotted
75000 Debentures - 75.00 Lakh raised
18 Nov 2022
Securities allotted
100000 Debentures - 1.00 cr raised
03 Nov 2022
Securities allotted
75000 Debentures - 75.00 Lakh raised
19 Oct 2022
Securities allotted
175000 Debentures - 1.75 cr raised
16 Sep 2022
Securities allotted
150000 Debentures - 1.50 cr raised
25 May 2022
Securities allotted
45000 Debentures - 45.00 Lakh raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BB from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 39 security allotment(s) - amounts available in the full report.
29 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Dirak (India) Panel Fittings Private Limited | U25200KA1997PTC022676 | Bengaluru, Karnataka, India |
| Ashirwad Strips Private Limited | U27100PB2005PTC029030 | Mandi Gobindgarh, Punjab, India |
| Mkd Chem Private Limited | U24304UP2017PTC089655 | Agra, Uttar Pradesh, India |
| Neo Crafts Impex Private Limited | U51909DL2010PTC205042 | Delhi, Delhi, India |
| Sephora Cosmetics Private Limited | U24246DL2007PTC162807 | New Delhi, Delhi, India |
| Hangal Coffee Exporting Private Limited | U51909KA2018PTC111622 | Mysore, Karnataka, India |
| Medybiz Pharma | U24117KA2009PTC051603 | Bangalore, Karnataka, India |
| Onyx Components And Systems Private Limited | U52334TG1995PTC019825 | Hyderabad, Telangana, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Lyruslife before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Lyruslife: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 25/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Lyruslife - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 72/100, distress signals and MSME payment-delay disclosures - know whether Lyruslife pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Lyruslife - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Lyruslife an active company?
Lyruslife has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Lyruslife financially healthy?
Lyruslife has a Financial Health Score of 25/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Lyruslife?
Its overall Trust Score is 72/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Lyruslife?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.
Does Lyruslife have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Lyruslife up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Lyruslife?
Its Credit Risk Score is 25/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
